BRIEF published on 08/27/2024 at 13:05, 2 months 24 days ago Pharnext begins liquidation proceedings Creditors Liquidation Paris Commercial Court Pharnext Suspension Of Listing
BRIEF published on 08/27/2024 at 13:05, 2 months 24 days ago Pharnext entame une procédure de liquidation judiciaire Liquidation Judiciaire Tribunal De Commerce De Paris Suspension De Cotation Pharnext Créditeurs
PRESS RELEASE published on 08/27/2024 at 13:00, 2 months 24 days ago Ouverture d'une procédure de liquidation judiciaire Pharnext SCA, société biopharmaceutique en liquidation judiciaire après procédure de conciliation. Suspension de la cotation des actions Biopharmaceutique Liquidation Judiciaire Suspension Cotation Pharnext Procédure Conciliation
BRIEF published on 07/04/2024 at 20:05, 4 months 16 days ago Pharnext announces the termination of the financing contract granted by Néovacs Investors Termination Funding Pharnext Néovacs
BRIEF published on 07/04/2024 at 20:05, 4 months 16 days ago Pharnext annonce la résiliation du contrat de financement accordé par Néovacs Financement Investisseurs Pharnext Résiliation Néovacs
PRESS RELEASE published on 07/04/2024 at 20:00, 4 months 16 days ago Pharnext annonce la résiliation du contrat de financement accordé par Néovacs Pharnext annonce la résiliation anticipée du contrat de financement avec Néovacs suite à des cas de défaut. La société sollicite Global Tech Opportunities 13 pour son soutien Financement Pharnext Résiliation Néovacs Global Tech Opportunities
BRIEF published on 06/18/2024 at 18:35, 5 months 2 days ago Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 Pharnext Procédure De Conciliation CMT1A PXT3003 Tasly
BRIEF published on 06/18/2024 at 18:35, 5 months 2 days ago Pharnext announces the extension of the conciliation procedure until July 15, 2024 Pharnext Conciliation Procedure CMT1A PXT3003 Tasly
PRESS RELEASE published on 06/18/2024 at 18:30, 5 months 2 days ago Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 pour poursuivre l'étude clinique de Phase III de PXT3003. Les résultats seront communiqués prochainement Conciliation Étude Clinique Pharnext PXT3003 Maladie Neurodégénérative
BRIEF published on 05/07/2024 at 19:15, 6 months 13 days ago Adjustment of the nominal value at Pharnext Biopharmaceutical Capital Reduction Pharnext Nominal Value Neurodegenerative Diseases
Published on 11/21/2024 at 09:00, 58 minutes ago ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 23 minutes ago Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 9 hours 33 minutes ago Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 00:00, 9 hours 58 minutes ago Swiss Mining Institute Conference Presentation
Published on 11/20/2024 at 23:00, 10 hours 58 minutes ago Rektron Group Inc. Announces Appointment of a New Director and Provides Corporate Updates
Published on 11/21/2024 at 09:41, 17 minutes ago Original-Research: 2G Energy AG (von First Berlin Equity Research GmbH): Buy
Published on 11/21/2024 at 08:59, 58 minutes ago Black Friday Savings: Kling AI Offers 50% Off and Free Feature Upgrades
Published on 11/21/2024 at 08:59, 58 minutes ago Économies Black Friday : Kling AI propose 50 % de réduction et des mises à niveau gratuites des fonctionnalités
Published on 11/21/2024 at 08:15, 1 hour 43 minutes ago EBIT increases to EUR 55.6 million. Equity (net asset value) increases by EUR 49.3 million to EUR 300.3 million, which corresponds to 70.14 euros per share. The equity ratio rises to 94.85%.
Published on 11/21/2024 at 06:58, 3 hours ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 3 hours ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 3 hours ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 13 hours 51 minutes ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 14 hours 38 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting